[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Research Letter
    August 14, 2019

    Evolving Practice Patterns in the Use of Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer

    Author Affiliations
    • 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
    • 2Department of Radiation Medicine, Oregon Health & Science University, Portland
    JAMA Netw Open. 2019;2(8):e199135. doi:10.1001/jamanetworkopen.2019.9135

    The recent phase 3 trial by Takahashi et al1 showed no overall survival benefit with prophylactic cranial irradiation (PCI) over active magnetic resonance imaging (MRI) surveillance among patients with extensive-stage small cell lung cancer (ES-SCLC), questioning the previously established benefit of PCI for this patient group.2 Consequently, in 2018, the National Comprehensive Cancer Network3 established equipoise between MRI surveillance and PCI in ES-SCLC. These developments have fueled debate over the role of PCI in this setting, and current practice patterns remain unclear.4 We conducted a nationwide survey study of radiation oncologists (ROs) to assess changes in the use of PCI for patients with ES-SCLC following publication of the trial by Takahashi et al.1